Adam Reynolds

Research Assistant Professor

University of New Mexico
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Year:

2026

Year:

2026

Year:

2026

Sex differences in melanoma are prominent, with female having a significant survival advantage. However, it is unclear why we see this survival advantage. Here, we investigate the relationship between sex, clinicopathologic variables, and melanoma specific survival in 1753 single primary melanomas from patients in the GEM (Genes, Environment, and Melanoma) study. Using Cox proportional hazard models and formal mediation analysis, the effect of sex on survival is explained largely by differences in the clinicopathologic features of tumors at diagnosis. Specifically, we find evidence that 86.5% of the effect of sex on melanoma survival is mediated by differences in age at diagnosis, Breslow thickness, ulceration, mitoses, and site (hazard ratio [HR] = 1.85, P < .001). This analysis indicates that the female survival advantage in melanoma is not primarily due to a direct effect of sex (HR = 1.19, P = .42) but is largely a result of an indirect effect of sex mediated by clinicopathologic features.

Year:

2025

Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.

Year:

2025

Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.

Year:

2025

Objectives Comparisons between Indigenous peoples over time and within a particular geographic region can shed light on the impact of environmental transitions on the skeleton, including relative bone strength, sexual dimorphism, and age‐related changes. Here we compare long bone structural properties of the inhabitants of the late prehistoric‐early historic Pecos Pueblo with those of present‐day Indigenous individuals from New Mexico. Materials and Methods Femora and tibiae of 126 adults from Pecos Pueblo and 226 present‐day adults were included in the study. Cross‐sectional diaphyseal properties—areas and second moments of area—were obtained from past studies of the Pecos Pueblo skeletal sample, and from computed tomography scans of recently deceased individuals in the present‐day sample. Results Femora and tibiae from Pecos individuals are stronger relative to body size than those of present‐day Indigenous individuals. Present‐day individuals are taller but not wider, and this body shape difference affects cross‐sectional shape, more strongly proximally. The tibia shows anteroposterior strengthening among Pecos individuals, especially among males. Sexual dimorphism in midshaft bone shape is stronger within the Pecos Pueblo sample. With aging, Pecos individuals show more medullary expansion but also more subperiosteal expansion than present‐day individuals, maintaining bone strength despite cortical thinning. Discussion Higher activity levels, carried out over rough terrain and throughout adult life, likely explain the relatively stronger lower limb bones of the Pecos individuals, as well as their greater subperiosteal expansion with aging. Greater sexual dimorphism in bone structure among Pecos individuals potentially reflects greater gender‐based differences in behavioral patterns.

Year:

2024

Year:

2024

At the headwaters of the Yenisei River in Tuva and northern Mongolia, nomadic pastoralists move between camps in a seasonal rotation that facilitates their animals' access to high-quality grasses and shelter. The use and informal ownership of these camps depending on season helps illustrate evolutionary and ecological principles underlying variation in property relations. Given relatively stable patterns of precipitation and returns to capital improvement, families generally benefit from reusing the same camps year after year. We show that locations with higher economic defensibility and capital investment—winter camps and camps located in mountain/river valleys—are claimed and inherited more frequently than summer camps and camps located in open steppe. Camps are inherited patrilineally and matrilineally at a ratio of 2 : 1. Despite its practical importance, camp inheritance is not associated with livestock wealth today, which is better predicted by education and wealth outside the pastoral economy. The relationship between the livestock wealth of parents and their adult children is significantly positive, but relatively low compared to other pastoralists. The degree of inequality in livestock wealth, however, is very close to that of other pastoralists. This is understandable considering the durability and defensibility of animal wealth and economies of scale common across pastoralists. This article is part of the theme issue ‘Evolutionary ecology of inequality’.

Year:

2023

Year:

2023

Collaborators (30)

Yuting Lu

New York University

UNITED STATES
View details

Graham Mann

Professor

University of Sydney

AUSTRALIA
View details

Shaofeng Yan

-

UNITED STATES
View details

John Ziker

Professor

Boise State University

UNITED STATES
View details

Yongzhao Shao

New York University Grossman School of Medicine

UNITED STATES
View details

Cheryl Thompson

Professor and Associate Director for Population Sciences, Penn State Cancer Institute

Pennsylvania State University

UNITED STATES
View details

Paul L. Hooper

Adjunct Associate Professor of Anthropology

University of New Mexico

UNITED STATES
View details

Christopher I. Amos

Associate Director for Population and Data Science

Baylor College of Medicine

UNITED STATES
View details

Jessica Valdez

Associate Professor; Attending Physician

University of New Mexico

UNITED STATES
View details

Pauline Funchain

Stanford University

UNITED STATES
View details

Marcus Bosenberg

Professor

Yale University

UNITED STATES
View details

Marianne Berwick

Professor

University of New Mexico

UNITED STATES
View details

David Ollila

Professor of Surgery

University of North Carolina at Chapel Hill

UNITED STATES
View details

Marc Ernstoff

Chief

National Institutes of Health

UNITED STATES
View details

Anne E Cust

Deputy Director, The Daffodil Centre

University of Sydney

AUSTRALIA
View details

Matthew Turner

Lecturer

Stanford University

UNITED STATES
View details

David Polsky

Alfred W. Kopf, M.D. Professor of Dermatologic Oncology and Professor (Clinical) of Pathology (Academic)

NYU School of Medicine

UNITED STATES
View details

Tea Jashashvili

Assistant Professor

University of Southern California Keck School of Medicine

UNITED STATES
View details

Tim Lee

The University of British Columbia

UNITED STATES
View details

Pei-Fen Kuan

Professor

Stony Brook University

UNITED STATES
View details

Paul Googe

Professor and Laboratory Director

University of North Carolina at Chapel Hill

UNITED STATES
View details

Stefani A. Crabtree

Utah State University

UNITED STATES
View details

Hoda Anton-Culver

Professor and Chair

University of California, Irvine

UNITED STATES
View details

James Wilmott

Associate Professor

The University of Sydney Library

AUSTRALIA
View details

Iman Osman

NYU Langone Health

UNITED STATES
View details

Eva Hernando

Professor

NYU Langone Medical Center

UNITED STATES
View details

Sheri L. Holmen

Professor

University of Utah Health Sciences Center

UNITED STATES
View details

James Jones

Professor

Stanford University

UNITED STATES
View details

Richard A. Scolyer

Faculty Member

University of Sydney

AUSTRALIA
View details

E. Nagore

Profesor Asociado

Universidad Católica de Valencia San Vicente Mártir Facultad de Medicina Facultad de Medicina y Odontología

SPAIN
View details